The START Center for Cancer Research has formed a strategic partnership with clinical research solutions provider Advarra to enhance speed, quality, and predictability in early-phase oncology trials. The collaboration will streamline trial workflows across START’s global community-based site network using Advarra’s regulatory and technology platforms.

START will adopt Advarra’s Independent Review Board (IRB) and Institutional Biosafety Committee (IBC) services as its preferred choice, alongside deploying the OnCore Clinical Trial Management System (CTMS) integrated electronic regulatory management system, eReg. This will support secure, end-to-end regulatory document management across all participating trial sites.

“Oncology drug development companies are under intense pressure to deliver innovative treatments to patients swiftly and reliably,” said Nick Slack, chairman and CEO of START. “By partnering with Advarra, we are building a truly interconnected ecosystem, leveraging the best technology and regulatory expertise in the industry. This will significantly enhance operational efficiency, compliance, and quality—accelerating delivery of breakthrough therapies while upholding patient safety.”

Advarra’s OnCore CTMS already supports more than 85% of NCI-designated cancer centres and has been active within START’s network since 2024. The partnership represents a major investment in infrastructure and operational excellence to connect patients, physicians, and advocacy groups with community-based cancer trials.

“Advarra is honored to support START in fulfilling its mission of bringing cutting-edge cancer treatments to patients,” said Gadi Saarony, CEO of Advarra. “We aim to remove barriers to research and streamline the path from discovery to care, helping expand START’s reach and impact globally.”

Key points:

• Partnership integrates Advarra’s IRB, IBC, and OnCore CTMS platforms with START’s global site network

• Deployment of eReg electronic regulatory management system ensures secure, end-to-end compliance

• Collaboration aims to speed early-phase oncology trials and improve trial quality and predictability

• Focus on patient-centric workflows linking community sites, physicians, and advocacy groups

• Supported by extensive experience in oncology research and clinical trial technology